Please login to the form below

Not currently logged in
Email:
Password:

GSK's Lawson elected PAGB president

He will help lead OTC trade body after departure of Novartis' David Barnett
pagb Carlton Lawson

The Proprietary Association of Great Britain (PAGB), which represents OTC companies in the UK, has elected Carlton Lawson of GlaxoSmithKline (GSK) as its new president.

On March 3 Lawson, who is general manager of GSK's consumer health business in the UK and Ireland, will take over from Novartis' David Barnett who moves to a new position in Latin America.

Lawson was only appointed to his current GSK position last year having previously served as global business lead in oral heath at the healthcare giant.

This followed a career that included senior sales and brand roles at Warner Lamber, Pfizer and Johnson & Johnson. He has experience with the PAGB too, being elected vice president in 2007.

Matthew Speers, chief executive of the PAGB, said he was “looking forward to working with Lawson”.

“Having served on the PAGB board previously when he was general manager at Johnson & Johnson, he has in-depth knowledge of PAGB and this past experience will be a great asset in helping drive forward PAGB's work programme, particularly the better regulation agenda,” said Speers.

26th February 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics